Publications by authors named "Kseniia Ievleva"
Context: Previous studies have shown that the prevalence of polycystic ovary syndrome (PCOS) may vary according to race/ethnicity, although a few studies have assessed women of different ethnicities who live in similar geographic and socioeconomic conditions.
Objective: To determine the prevalence of PCOS in an unselected multiethnic population of premenopausal women.
Design: A multicenter prospective cross-sectional study.
Polycystic ovary syndrome (PCOS) is a highly prevalent disorder in women, and its diagnosis rests on three principal features: ovulatory/menstrual dysfunction, clinical and/or biochemical hyperandrogenism, and polycystic ovarian morphology (PCOM). Currently, data on age- and ethnicity-dependent features of PCOM remain insufficient. We aimed to estimate ethnicity- and age-dependent differences in ovarian volume (OV) and follicle number per ovary (FNPO) in a healthy, medically unbiased population of Caucasian and Asian premenopausal women, who participated in the cross-sectional Eastern Siberia PCOS epidemiology and phenotype (ESPEP) study (ClinicalTrials.
View Article and Find Full Text PDFAbnormalities in gut microbiota diversity are considered important mechanisms in metabolic disorders in polycystic ovarian syndrome (PCOS). However, the data on the association of these disorders with the PCOS phenotype remain controversial. The objectives of this study were to estimate the alpha diversity of the gut microbiota of healthy women and PCOS patients depending on phenotype.
View Article and Find Full Text PDFAndrogen assessment is a key element for diagnosing polycystic ovary syndrome (PCOS), and defining a "normal" level of circulating androgens is critical for epidemiological studies. We determined the upper normal limits (UNLs) for androgens in a population-based group of premenopausal "healthy control" women, overall and by ethnicity (Caucasian and Asian), in the cross-sectional Eastern Siberia PCOS Epidemiology and Phenotype (ESPEP) Study (ClinicalTrials.gov ID: NCT05194384) conducted in 2016-2019.
View Article and Find Full Text PDFArticle Synopsis
- Recent research highlights follicle-stimulating hormone (FSH) as a target for treating diseases like osteoporosis, obesity, and Alzheimer's, with findings showing that blocking FSH can prevent various health issues in mice.
- The development of a humanized FSH-blocking antibody called MS-Hu6 has shown promise in preventing osteoporosis in mice and has safe initial testing in monkeys, demonstrating effective localization to bone and bone marrow.
- MS-Hu6 has been optimized for stability and safety, showing no immunogenic responses in human cell cultures, making it ready for potential future human clinical trials.
Leydig cell tumors (LCTs) refer to tumors of the stroma of the genital strand, which are found mainly in postmenopausal women. The diagnosis of LCTs in postmenopausal women is associated with specific difficulties and is based on the identification of hyperandrogenism with clinical manifestations of virilization, which has an erased picture in postmenopausal women. LCTs require differential diagnosis with other causes of hyperandrogenism.
View Article and Find Full Text PDFArticle Synopsis
- - Alzheimer's disease is more common in older women, especially during menopause, and is linked to factors like body fat, energy regulation, and bone loss.
- - In mice, reducing follicle-stimulating hormone (FSH) levels leads to decreased body fat, improved bone health, and lower cholesterol.
- - The study shows that FSH contributes to Alzheimer's symptoms by accelerating harmful protein buildup in the brain, and blocking FSH can potentially help treat Alzheimer's and related conditions.
First-in-class humanized FSH blocking antibody targets bone and fat.
Proc Natl Acad Sci U S A
November 2020
Article Synopsis
- Blocking FSH in mice leads to reduced body fat, lower cholesterol levels, and increased bone mass, suggesting potential treatment for obesity, osteoporosis, and high cholesterol.
- Researchers developed a fully humanized antibody that effectively blocks FSH, demonstrating strong binding and stability in tests.
- This new antibody significantly inhibits FSH activity in lab assays, paving the way for future testing in preclinical and clinical settings.
Article Synopsis
- Research in biomedicine is increasingly relying on knowledge and technologies from various fields, making collaboration essential.
- The authors share insights gained from working in interdisciplinary and transdisciplinary teams.
- Their experiences encouraged them to broaden their research focus beyond just bone biology.
Article Synopsis
- Two common erectile dysfunction drugs, tadalafil and vardenafil, help increase bone density in mice by promoting bone formation and inhibiting bone loss.
- These drugs work by targeting the enzyme phosphodiesterase 5A (PDE5A), which is found in both bones and certain brain areas, suggesting a complex interaction between bone health and the nervous system.
- Interestingly, while vardenafil is more effective than tadalafil in humans, the opposite is true in mice, likely due to differences in how these drugs bind to the mouse version of PDE5A.
The primitive neurohypophyseal nonapeptide oxytocin (OXT) has established functions in parturition, lactation, appetite, and social behavior. We have shown that OXT has direct actions on the mammalian skeleton, stimulating bone formation by osteoblasts and modulating the genesis and function of bone-resorbing osteoclasts. We deleted OXT receptors (OXTRs) selectively in osteoblasts and osteoclasts using and mice, respectively.
View Article and Find Full Text PDF